ABSTRACT -Many chemicals released into the environment potentially disrupt the endocrine system in wildlife and humans. Some of these chemicals exhibit estrogenic activity by binding to the estrogen receptors. The developing organism is particularly sensitive to estrogenic chemicals during the critical period in which the induction of long-term changes and persistent molecular alterations in female reproductive tracts occur. Perinatal mouse and rat models can be utilized as indicators for determining the consequences of exposure to exogenous estrogenic agents, including possible xenoestrogens or environmental endocrine disruptors. Estrogen receptors (ER) and estrogen responsive genes, therefore, need to be identified in order to understand the molecular basis of estrogenic actions. Recent identifications of ER subtypes and isoforms make understanding target organ responses to these estrogenic chemicals even more difficult. Indeed, many reports suggest that these chemicals do affect the reproductive and developmental processes of female laboratory rodents that had been perinatally exposed, and that interactions between sex steroid hormone receptors occur. Much information concerning the expression of sex steroid receptors in rodents has been reported concerning the normal development of the Müllerian duct. Thus, accumulated information on the expression of ER subtypes and isoforms as well as that of progesterone and androgen receptors in laboratory rodents is herein reviewed, in addition to the presentation of our own data.
INTRODUCTION
Recently, there has been considerable concern about the potential endocrine-disrupting effects of chemicals released into the environment in wildlife and humans (Colborn and Clement, 1992) . Chemicals that have estrogenic activity are termed xenoestrogens or endocrine disruptors. They are thought to mimic or disturb the action of estrogen and many of them are known to possess estrogen receptor-binding activity (Danzo, 1997) . This fact brings to mind historical work by Herbst et al. done in the early seventies (1971) when a close correlation between the occurrence of vaginal clear cell adenocarcinoma in young women and early intrauterine exposure to diethylstilbestrol (DES), a synthetic estrogen, was demonstrated (Herbst and Bern, 1981) . Similarly, during prenatal and neonatal development of the paramesonephric or Müllerian duct, estrogen exposure has been found to induce a variety of abnormalities in the Müllerian derivatives such as uncoiling of the oviduct and uterine hyperplasia in addition to neoplasia, vaginal hyperplasia and ovaryindependent cornification with an abnormal cell proliferation rate in mice and rats (Dunn and Green, 1963; Takasugi and Bern, 1964; Iguchi and Takasugi, 1987; Newbold et al., 1983; Iguchi, 1992; Sato et al., 1994 Sato et al., , 2004 Okada et al., 2001) . Laboratory rodents exposed perinatally to estrogens, therefore, provide a model for the exploration of the consequences of xenoestrogen exposure in humans, since rodent genital tract development at birth is similar to that of the human fetus at the end of the first trimester.
Recent developments in molecular and cellular biology techniques have identified many subtypes and isoforms of sex steroid hormone receptors and the complex interaction between them. The specific importance of subtypes and isoforms of estrogen receptor (ER) and progesterone receptor (PR) in reproductive and non-reproductive tissues was proposed in ER or PR knockout mice (Lubahn et al., 1993; Krege et al., 1998; Conneely and Lydon, 2000; Dupont et al., 2000; Conneely et al., 2003) . However, reproductive tract development is normal during the prenatal and neonatal stages in the knockout mice, suggesting that ER and PR signals are not necessary for the morphogenesis of the female reproductive tract. Nevertheless, as described above, perinatal administration of estrogens exerts teratogenic and carcinogenic effects on female rodent reproductive tracts. Findings in estrogen receptor α knockout (αERKO) mice and in transgenic mice which overexpress ERα lead to the speculation that the teratogenic and carcinogenic effects of estrogens are mediated through ERα (Couse et al., , 2001 ). There have been accumulating reports regarding the expression pattern of sex steroid hormone receptors in the developing female reproductive tracts in mice and rats. This information allows us to understand which cells and tissues are targets for physiological and exogenous estrogens. The prenatal and neonatal ontogenies of sex steroid hormone receptors in female reproductive tracts have been reported (Pasqualini and Sumida, 1986; Greco et al., 1993) . However, experiments have been performed using radio-labeled ligands or immunohistochemistry with the antibody, both of which are non-specific to the receptor subtypes or isoforms (Murakami et al., 1990) . Thus, in order to have a better understanding of the molecular and cellular mechanisms underlying effects of sex steroid hormones during the development of female reproductive tracts, this article will review recent progress in the subtype and isoform expression of ER in laboratory rodents, as well as those of PR and androgen receptor (AR).
PR is one of the well-studied estrogen-regulated genes that contain estrogen response elements (ERE) (Kastner et al., 1990; Kraus et al., 1994) . Previous reports demonstrated that progesterone-binding sites and PR expression were regulated by the estrogens in female reproductive tracts (Ennis and Stumpf, 1988; Ohta et al., 1996; Okada et al., 2002b) . Kurita and coworkers (2000) showed mechanistic evidence of PR regulation by estradiol (E2) in mouse uterine and vaginal epithelia in vivo in tissue recombinants made with epithelium and stroma from wild-type and/or αERKO mice. They suggested paracrine regulation via stromal ERα and direct regulation via epithelial ERα in mouse uterus and vagina, respectively. Androgens also have uterotrophic effects in intact and ovariectomized immature female rats (Armstrong et al., 1976) , and testicular feminized male (Tfm/Tfm) mice show impaired reproductive performance (Lyon and Glenister, 1980) , both of which suggest the importance of androgens in female reproduction (Kowalski et al., 2004) . Weihua et al. (2002) have recently reported the essential role of AR in estrogen-induced uterine epithelial cell proliferation in rats, and they indicated that stromal AR amplified the ERα signal by induction of insulin-like growth factor I (IGF-I), which is known to be produced in stromal cells and induce epithelial cell proliferation in a paracrine fashion. Moreover, direct inhibitory effects of the ERα/AR heterodimer on both ERα and AR transactivational properties have been reported (PanetRaymond et al., 2000) . Thus, identification of regional and cellular AR and PR localization may allow a better understanding not only of the role of AR and PR, but also the mechanism of estrogen action in female reproductive tracts.
A brief description of the development of the female reproductive tract
In mammals, both the paramesonephric or Mülle-rian duct and the mesonephric or Wolffian duct are situated within the genital ridge. There are two ducts present during fetal development. The Müllerian duct develops in the cranial to caudal direction along with the Wolffian duct during gonad formation (Dohr and Tarmann, 1984; Byskov and Høyer, 1994) . After gonad differentiation, androgens produced by Leydig cells induce Wolffian duct development, and Müllerian inhibiting substance (MIS) produced by Sertoli cells induces Müllerian duct degeneration in male fetuses. In female fetuses, Müllerian duct development and Wolffian duct degeneration occur due to a lack of androgens and MIS after gonadal differentiation (Josso and Picard, 1986) . Thus, male reproductive organs such as the epididymis, vas deferens, and seminal vesicles arise from the Wolffian duct, and female reproductive organs such as the oviduct, uterus, and upper vagina arise from the Müllerian duct.
The Müllerian duct is comprised of epithelial cells surrounded by mesenchymal cells. The pattern of cell proliferation of the Müllerian duct has been demonstrated in prenatal, immature, and adult rodents (McCormack and Glasser, 1980; Quarmby and Korach, 1984; Li, 1994; Okada et al., 2001) . In tissue recombination experiments, epithelial-mesenchymal interactions are critically important for the proper differentiation of the Müllerian duct derivatives (Kurita et al., 2001) . At birth, Müllerian epithelium is negative for uterine and vaginal epithelial markers, and uterine and vaginal gene expression patterns are induced in neonatal Müllerian epithelium by the respective mesenchymes. Kurita et al. (2001) also showed that functional differentiation of uterine and vaginal epithelia required organ-specific mesenchymal/stromal factors, but mesenchymal/stromal signals regulating proliferation of epithelial cells in the uterus and vagina appeared to be nonspecific. Since it is well known that the functional differentiation of uterine and vaginal epithelia is regulated by E2 and progesterone (P4), mesenchymal/stromal signals for regulating functional epithelial differentiation may be controlled through mesenchymal/stromal ERs and PRs. Thus, temporal expressions of these receptors may be helpful for understanding Müllerian duct development.
Subtypes and isoforms of estrogen and progesterone receptors
Estrogen, progesterone, and androgen actions are mediated by ERs, PRs, and AR, respectively, which belong to the nuclear receptor superfamily of ligandinducible transcription factors (Mangelsdorf et al., 1995) . The steroid hormone receptor-ligand complex binds target DNA at hormone response elements (HREs) to transcribe various downstream genes such as oncogenes and genes encoding growth factors. In rats, two subtypes of ERs, classical ERα (Koike et al., 1987) and novel ERβ (Kuiper et al., 1996) have been identified. ERβ was also cloned in mice (Tremblay et al., 1997) and humans (Mosselman et al., 1996) , showing high homology between the species. E2 bound ERα with a higher affinity than ERβ and increased ERα transcriptional activity at the EREs in a reporter assay Pettersson et al., 2000) . In addition to these differences in transcriptional activity, ERα and ERβ can have entirely opposite transcriptional effects at activating protein-1 (AP-1) sites, depending on the ligands (Paech et al., 1997) . Moreover, the role of ERβ as a negative regulator of ERα has been suggested in mouse uterus (Weihua et al., 2000) . Five isoforms of ERβ mRNA, ERβ1 (ERβ), ERβ2, ERβ1-δ3, ERβ2-δ3, and ERβ1-δ4, have been reported in various rat tissues as products of alternative splicing (Maruyama et al., 1998; Petersen et al., 1998; Price et al., 2000) . Only ERβ1 and ERβ2, which has an additional 18 amino acids in the ligand binding domain of ERβ1, have the ability to bind both ligand and ERE. However, ERβ2 has an apparently lower binding affinity for E2 as compared to ERβ1 (Petersen et al., 1998) . Therefore, ERβ2 can act as a dominant negative regulatory partner during heterodimerization with ERα or ERβ1. This action has been demonstrated during rat mammary gland development (Saji et al., 2001) .
Two PR isoforms, PR-A and PR-B, are produced from a single gene by transcription at two distinct promoter sites Kastner et al., 1990; Savouret et al., 1990) . The expression of two protein isoforms from the one gene is conserved in several species, including mice, rats, and humans (Lessey et al., 1983; Schott et al., 1991; Kraus et al., 1993) . The human PR-A isoform differs from the PR-B in that it lacks 164 amino acids on its N terminus. The ratio of isoforms varies depending on the reproductive tissues during development (Shyamala et al., 1990) and the estrous cycle (Mangal et al., 1997) . PR-A-and PR-Bdeficient mice suggest the different actions of each PR isoform in vivo (Lubahn et al., 1993; Krege et al., 1998; Conneely and Lydon, 2000; Dupont et al., 2000; Conneely et al., 2003) .
ONTOGENIC EXPRESSION OF ESTROGEN RECEPTORS

During prenatal development of the Müllerian duct
Immunohistochemistry of ERα and ERβ showed differential expression of the two ER subtypes in the ovaries and uterus of adult rats (Shughrue et al., 1998; Hiroi et al., 1999; Sar and Welsch, 1999; Wang et al., 1999; Mowa and Iwanaga, 2000a; Pelletier et al., 2000) . In female rodents, expression of ERα was detected in both the epithelium and stroma of the uterus and vagina (Sato et al., 1992 Ohta et al., 1993 Ohta et al., , 1996 Graham and Clarke, 1997; Mowa and Iwanaga, 2000a; Shughrue et al., 1998; Wang et al., 1999) . ERβ is reportedly expressed at a lower level than ERα in the uterus and vagina of adult mice and rats (Mowa and Iwanaga, 2000a; Shughrue et al., 1998; Wang et al., 1999) . ER is expressed in the Müllerian duct of fetal mice (Greco et al., 1991; Wu et al., 1992; Greco et al., 1993; Lemmen et al., 1999; Jefferson et al., 2000; Nielsen et al., 2000) and rats (Mowa and Iwanaga, 2000b) . Greco and co-workers (1991) reported that ER immunoreactivity was observed in epithelial cells of female mouse reproductive tract at 15 days post-coitus (dpc), but was occasionally observed at 17 dpc and on the day of birth. The results of immunohistochemistry with a monoclonal antibody specific to ERα in mice (Nielsen et al., 2000) , and in situ hybridization with a radio-labeled probe specific to ERα in rats (Mowa and Iwanaga, 2000b) demonstrate that ERα localization varies with the region of the Müllerian duct involved. Nielsen et al. (2000) detected a faint immunopositive signal in the nuclei of the surrounding cells of the Müllerian duct as early as 11.5 dpc in mice. Epithelial ERα was first observed in the proximal oviduct region at 13.5 dpc. At the mRNA level, expression of ERα was exhibited in the oviductal epithelium and all mesenchyme at 17 dpc. It was expressed in the uterine and vaginal epithelia on postnatal days. The semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR) study showed that the ERα mRNA level in the Müllerian duct at 21.5 dpc was 4.4-fold higher than that at 15.5 dpc in rats (Okada et al., 2002a) . In immunohistochemical evaluations, ERα protein showed a similar expression pattern to its mRNA (Table 1 ). In the oviduct region at 15.5 dpc, mesenchymal ERα staining could be detected, but epithelial staining was only slight. Epithelial and mesenchymal ERα levels within the oviduct region increased gradually from 15.5 dpc to 19.5 dpc. Uterine and vaginal ERα levels continually increased within the mesenchyme throughout gestational development and reached marked intensity levels by 21.5 dpc. However, epithelial ERα staining was slight or absent from the uterine and vaginal regions throughout gestation until 21.5 dpc. Although this study evaluated ERα expression in the upper vagina, which originated from the Müllerian duct, earlier ERα expression at 16 dpc was detected in the epithelium of the lower vagina, which was derived from the urogenital sinus in mice (Kurita et al., 2001 ). These observations clearly demonstrate that ERα is expressed region-and cell typedependently during the prenatal development of the Müllerian duct. The patterns of ERα localization suggest potential tissue-specific mechanisms by which estrogenic chemicals may influence Müllerian duct cell growth and differentiation.
No expression of ERβ1 (ERβ) was detected in the mouse uterus at 16 dpc in the ribonuclease protection assay (RPA) (Jefferson et al., 2000) . Two in situ hybridization studies revealed similar negative results in the epithelium and mesenchyme of the Müllerian duct throughout the prenatal period in rats and mice (Lemmen et al., 1999; Mowa and Iwanaga, 2000b) . However, in the RT-PCR study, rat Müllerian duct ERβ1 and ERβ2 mRNAs were detected and found to be expressed at constant levels from 15.5 dpc to 21.5 dpc (Okada et al., 2002a) . Expression levels of ERβ1 and ERβ2 mRNA were much lower than that of ERα. Comparison of ERβ1 and ERβ2 expression levels indicated that ERβ2 mRNA expression is significantly greater than that of ERβ1 in the 19.5 dpc Müllerian duct. The tissue-specific expression ratio of ERβ1 ver- sus ERβ2 has been described in various rat tissues; approximately 1:1 in prostate, ovary, muscle, and pituitary, and 2-to 6-fold expression of ERβ1 compared to that of ERβ2 in tissues of the nervous system (Petersen et al., 1998) . Recently, the importance of ERβ2 as a negative regulator of ERα has been demonstrated in the rat mammary gland in which ERβ2 levels are comparable or higher than those for ERβ1 (Saji et al., 2001) . Although both ERβ1 and ERβ2 levels are obviously higher than ERα in the mammary gland, both isoforms were extremely low in rat Müllerian duct compared to ERα, implying insufficient amounts of ERβs acting as a negative regulator of ERα in the rat Müllerian duct. The physiological significance of ERβ2 in rat Müllerian duct is unknown, but different ratios of ERα/ERβ1/ERβ2 among tissues may suggest tissue-specific regulation depending on the ER subtypes and isoforms. Taken together, these results indicate that ERα is likely a dominant ER subtype during Müllerian duct development. Furthermore, region-specific ERα expression firmly indicates that functional differentiation within the Müllerian duct occurs before morphological differentiation during the neonatal period, and that regional targets for chemicals that may act via or influence ER-mediated mechanisms are specific during late gestational Müllerian duct differentiation.
During neonatal development of the oviduct
The mammalian oviduct, or fallopian tube, is part of the female reproductive tract that has a fundamental role in gamete transport, fertilization, and subsequent early embryo development (Jansen, 1984) . During neonatal development, the oviduct forms a coiled structure and is composed of four different regions: the infundibulum (INF), ampulla (AMP), isthmus (IST) and uterotubal junction (UTJ). Depending on the oviductal region, there are at least two types of epithelial cells: ciliated epithelial cells and nonciliated or secretory epithelial cells. Growth and development of these cell types are under regulation by the sex steroid hormones E2 and P4 (Abe and Oikawa, 1993) . ERα and ERβ expression in the rat oviduct has been reported (Saunders et al., 1997; Sar and Welsch, 1999; Iwanaga, 2000a, 2000b; Wang et al., 2000) , but the predominant ERα expression was shown in the neonatal oviduct. Oviductal ERβ expression was low in rats (Saunders et al. 1997 , Mowa and Iwanaga, 2000a , 2000b ) and mice , while Sar and Welsch (1999) and Jefferson et al. (2000) failed to detect ERβ immunopositive cells in the oviducts of rats or mice, respectively, at all. In a quantitative real-time RT-PCR study, oviductal ERα mRNA increased until neonatal day (ND) 3, and was maintained at a high constant level through ND 20. However, ERβ mRNA was detected in the oviduct in a low and constant manner, as compared with ERα, throughout pre-and postnatal development (Okada et al., 2003) . In the immunohistochemical study of cell-and region-specificity (Table 2) , epithelial ERα was weak at birth (ND 0) and exhibited moderate stainings from ND 3 to 20. However, some ERα negative cells were present in the epithelium of the INF/AMP region after ND 10. Stromal cells showed ERα staining at weak, moderate, and marked levels at ND 0, from ND 3 to 10, and ND 15 and 20, respectively, and no marked difference in ERα staining was noted between regions in the oviduct. Moderate ERα staining was also found in muscle cells of the IST/UTJ region from ND 7 to 20. ERβ immunoreactivity was indistinguishable in the neonatal oviduct. Thus, abundant ERα may be a major ER subtype and play an essential role in the development and function of the neonatal rat oviduct.
As described above, in the developing rat oviduct, ERα was expressed in both epithelial and stromal cells, and the staining intensity and mRNA level increased with the growth of the neonates. With the increases in these receptors during the early postnatal period, immunoreactivity for β-tubulin IV, a cilia marker protein, in the rat oviduct appeared between ND 5 and ND 7. Komatsu and Fujita (1978) have reported in their electron-microscopy study that the differentiation of ciliated cells, which is believed to be elicited by the initiation of endogenous estrogen production, occurs in the mouse oviduct on ND 5. Furthermore, neonatal E2 administration accelerated cilia formation in the mouse and rat oviduct (Eroschenko, 1982; Okada et al., 2004a Okada et al., , 2004b . Although the stimulation of ER signaling accelerates the differentiation process of ciliated epithelial cells, the presence of cilia in the αERKO mouse oviduct suggests that it is not fundamentally required for this event in the ERα-negative ciliated epithelial cells of the adult oviduct (Okada et al., 2004a) . Double immunohistochemical staining for ERα with β-tubulin IV was reported in the determination of surface epithelial cell types expressing ERα (Okada et al., 2003) . The ciliated cells were positive for β-tubulin IV, while the nonciliated (secretory) cells were negative for it. ERα was selectively observed in nonciliated epithelial cells, but not in ciliated epithelial cells of the INF/AMP. In contrast, almost all epithelial cells in the UTJ/IST were negative for β-tubulin IV, but positive for ERα.
During neonatal development of the uterus and vagina
Region-specific expression of ER was previously reported in the female reproductive tracts of neonatal mice. On the day of birth, ER was expressed in epithelial cells of the oviduct, cervix and vagina, but not in the uterus. In contrast, stromal cells expressed ER in all of these organs, including the uterus (Yamashita et al., 1989; Sato et al., 1992 Sato et al., , 1996 Ohta et al., 1993 Ohta et al., , 1996 Li, 1994; Fishman et al., 1996) . The onset of uterine epithelial ER immunostaining was ND 4 in mice (Yamashita et al., 1989) and ND 5 in rats (Table 3 , Ohta et al., 1996) . ER mRNA was observed starting on ND 7 in rats (Fishman et al., 1996) . However, strain differences in the ontogenetic localization of ER were reported in uterine epithelial cells of neonatal BALB/c and CD-1 mice (Bigsby et al., 1990) . Mowa and Iwanaga (2000b) evaluated ERα expression in the neonatal female rat reproductive tract using in situ hybridization. No ERα mRNA signals were found in the uterine, cervical or vaginal epithelia until ND 4-6. The first appearance of ERα mRNA signals in uterine and vaginal epithelia was recognized by ND 4 and 6, respectively. In the vagina, the strongest and most distinct signals for ERα mRNA were localized in the basal layer of the epithelium and diminished in strength towards the lumen. Uterine glandular epithelium expressed signals for ERα mRNA by ND 14. The cervix was the only portion of the developing reproductive tract lacking epithelial ERα. Jefferson et al. (2000) also revealed postnatal ERα and ERβ expression in the female mouse reproductive tract using RPA and immunohistochemistry. The results of RPA revealed that the expression of ERα mRNA in the uterus was found at all stages of neonatal development, but no ERβ mRNA appeared until ND 26. Moreover, in immunohistochemistry, ERα was detected in stromal cells of the uterus throughout the postnatal period and in epithelial cells as early as ND 5. Similarly, ERα immunostaining was detected on ND 5 in mouse uterine epithelium, and at birth in both the Müllerian and sinus vagina (Kurita et al., 2001) . Signals for ERβ mRNA were only weakly expressed in the reproductive tract during the rat postnatal period (Mowa and Iwanaga, 2000b) , and there was no expression of ERβ protein in the mouse uterus (Jefferson et al., 2000) .
ONTOGENIC EXPRESSION OF PROGESTERONE RECEPTORS
During prenatal development of the Müllerian duct
In adult rodents, expression of PR has been reported in both the epithelium and the stroma of the uterus and vagina (Ohta et al., 1993 Graham and Clarke, 1997; Mowa and Iwanaga, 2000a; Shughrue et al., 1998; Wang et al., 1999) . Developmental changes in PR have been reported in the uterus of guinea pigs and rats using binding assay with radio-labeled ligand (Pasqualini and Nguyen, 1980; Nguyen et al., 1988) , showing a developmental increase in P4 binding sites. In the RT-PCR study, PR mRNA expression was detected from 15.5 dpc and increased gradually by 21.5 dpc in the rat fetus (Okada et al., 2002b) . Significant increases were exhibited on 21.5 dpc compared to 15.5 dpc and 17.5 dpc. Localization of PR protein was assessed during rat development by immunohistochemistry using a monoclonal antibody against both PR-A and PR-B (PR-A+B) (Table 4) . PR-A+B immunostaining was localized within the nuclei of the Mül-lerian epithelium. Although the vagina had not yet been formed by 15.5 dpc, slight epithelial PR staining could be detected in the oviduct and uterus by this time. Weak staining of Müllerian epithelial PR appeared in the upper vaginal region by 17.5 dpc. The intensity of Müllerian epithelial PR staining increased gradually from 15.5 dpc until 19.5 dpc within all three of the regions. Staining levels became constant by 19.5 dpc and moderate staining appeared through 21.5 dpc. In contrast, mesenchymal PR staining was faint in all regions of the Müllerian duct throughout gestational development (Okada et al., 2002b) . Kurita et al. (2001) also reported negative immunostaining for PR-A+B in mesenchymal cells of the uterus, upper vagina, and lower vagina during prenatal development in mice. In order to investigate the differential expression of PR isoform mRNAs in the oviduct, two distinct primer pairs were used; one detected A and B isoforms equally and the other was specific for B isoform (Okada et al., 2003) . Oviductal PR-A+B and PR-B were equally expressed at low levels from 15 dpc until birth.
During neonatal development of the oviduct
Neonatal development of oviductal epithelial cells is regulated by E2 and P4 (Abe and Oikawa, 1993) . Neonatal PR-A+B ontogeny in oviduct has been reported in mice (Li, 1994) and rats (Okada et al., 2003) . Li (1994) demonstrated that in mice, staining of the epithelial PR was weak to positive from ND 1 to 3, Ohta et al. (1996) Epi and moderately positive from ND 7, stromal and muscular PR was evident from ND 1. In our rat study, PR immunoexpression was evident in epithelial cells at slight levels at birth, however, it was not present in stromal cells (Table 2) . Slight epithelial PR expression continued until ND 5 in the undifferentiated oviduct, and until ND 20 in the INF/AMP region. However, some epithelial cells showed a negative or moderate PR signal in the differentiated INF/AMP region from ND 7 to 20. A double immunohistochemical study on PR-A+B with β-tubulin IV revealed that PR-A+B is expressed specifically in ciliated epithelial cells, but not in nonciliated cells, the same as ERα (Okada et al., 2003) . In contrast, epithelial PR staining was intense in the differentiated IST/UTJ region, and showed moderate and marked signals on ND 7 to 10, and ND 15 to 20, respectively. PR was also detected in stromal cells after ND 3, but was absent from the IST/UTJ region on ND 7 to 10. Muscle cells showed slight and moderate PR staining in the IST/UTJ region on ND 10, and from ND 15 to 20, respectively. Oviductal PR-A+B and PR-B mRNAs were equally expressed at low levels from birth to ND 3, and both increased gradually from 15 dpc to ND 5. PR-A+B then increased markedly until ND 20, but PR-B expression continued to increase moderately from ND 7 to 20, resulting in a decrease in the percentage of PR-B to one tenth vs. one quarter against PR-A+B (Okada et al., 2003) . At present, although little evidence has been available to define the physiological significance of P4 action via PR-A and/ or PR-B, it seems highly probable that differential expression of the two isoforms in the oviduct is fundamental for cell growth, differentiation, and function in response to P4. PR-A is reportedly able to act as a transcriptional inhibitor of PR-B when both proteins are co-expressed (Vegeto et al., 1993) . Gava et al. (2004) described the differential expression of PR-A and PR-B between cell types in the cycling mouse oviduct. PR-A was the predominant isoform in the oviduct, observed within both epithelial and stromal cells of the AMP and IST regions. In contrast to PR-A expression, PR-B was detectable only in epithelial cells lining the AMP and IST regions.
During neonatal development of the uterus and vagina
Immunohistochemical uterine and vaginal PR expression has been described in mice (Li, 1994; Kurita et al., 2001 ) and rats (Ohta et al., 1993 . Li (1994) detected positive PR staining in uterine epithelial cells at birth. However, other reports failed to detect PR at birth, but first detected it on ND 3 in mice and ND 5 in rats (Table 3, Ohta et al., 1996) . Uterine epithelial PR increased with subsequent postnatal development in both mice and rats. Similarly, uterine stromal and muscular cells expressed PR from birth in mice, but not in rats. Rat stromal and muscle PR was found in the uterus from ND 12 and ND 15, respectively. Kurita et al. (2001) evaluated vaginal PR expression during postnatal development in mice, but epithelial immunostaining for PR was negative from birth to ND 14 in both the Müllerian and sinus vagina. No report on isoform expression for uterine or vaginal PR during postnatal development has been found.
ONTOGENIC EXPRESSION OF ANDROGEN RECEPTOR
In rat uterus, AR has been identified by both immunohistochemistry and in situ hybridization in epithelial, stromal, and smooth muscle cells (Hirai et al., 1994) . In human vagina, AR immunoreactivity was found in both epithelial and stromal cells (Hodgins et al., 1998; Pelletier et al., 2000) . AR was also expressed in the female reproductive tracts of rat fetuses. Although AR levels were similar at 17 dpc in the urogenital tubercle of male and female fetuses, the amount of AR decreased after 18 dpc in female urogenital tissues (Bentvelsen et al., 1994) . AR mRNA was also expressed in the rat oviduct, and increased gradually with development of the pre-and neonatal rats (Okada et al., 2003) . Drews et al. (2001) investigated the immunohistochemical localization of AR in the Mülle-rian duct of fetuses at 17 dpc and 18 dpc. AR staining showed negative throughout the duct except for mesenchymal cells in the sinus region. In the developing oviduct, no AR immunoreactivity was detected on 15 dpc and 19 dpc ( Table 2 , Okada et al., 2003) . Both epithelial and stromal ARs were first detected at a low level on ND 3, and maintained at similar level until ND 20 in all oviduct regions. In the IST and UTJ, muscle AR was observed at slight and weak levels from ND 7 to 10, and ND 15 to 20, respectively. AR was predominantly detected in nonciliated epithelial cells in the INF/AMP, and stromal and muscle cells in the rat oviduct. Recently, a direct inhibitory effect of the ERα/ AR heterodimer on both ERα and AR transactivational properties has been reported (Panet-Raymond et al., 2000) . Although, in the rat oviduct, co-localization of AR and ERα has not been determined, both AR and ERα were expressed in stromal, muscle, and nonciliated epithelial cells. Interaction of AR and ERα, therefore, may possibly occur in the rat oviduct as well as in the uterus.
FINALLY
Xenoestrogens or endocrine disruptors bind ER and may cause estrogenic effects in humans. In laboratory rodents, perinatal exposure to estrogenic chemicals causes a variety of abnormalities in the female reproductive tract. Thus rats and mice have been used as a model system for the investigation of the perinatal effects of estrogenic chemicals to human embryos and fetuses. Meanwhile, several subtypes and isoforms of sex steroid hormone receptors, including ER, have been identified, and understanding the interactions between these subtypes and isoforms can shed light on the molecular mechanism of hormone action. In order to clarify the effect of estrogenic chemicals on the reproductive tract, it is essential to understand in which organs, on which cell types, and during what stages of development these chemicals can act. Accumulating evidence suggests that different receptor subtypes and isoforms showed developmental stage-, organ-and cell type-specific expression patterns in the female reproductive tract, demonstrating the importance of finding which are target organs and cells for each developmental stage. In addition, we need to elucidate the molecular mechanisms of estrogenic chemicals. Microarray methodology will provide a powerful technique for identifying global gene expression changes during development and for understanding the molecular basis of the adverse effects of the estrogenic chemicals that can alter signaling systems (Watanabe et al., 2002 (Watanabe et al., , 2003 (Watanabe et al., , 2004 Wu et al., 2003; Hu et al., 2004) . It is necessary to study targets of estrogenic chemicals with consideration to the developmental stage and with an understanding of the phenotypes that result from perinatal exposure, in addition to the changes in gene expression obtained from microarray and other molecular techniques.
